In this study, after using the NIMNT database to enrich the indications of HSYA, we found that hepatitis ranked first of 54 potential targets of HSYA, which is consistent with previous studies showing that HSYA can prevent inflammatory liver injury and liver fibrosis by inhibiting expressions of the inflammatory cytokines IL-1β, IL-6, and TNF-α [34,35]. Here, TNF is linked to Hepatic fibrosis.